CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/12/2019 10:30 PDT] CorMedix, Inc. (NYSE:CRMD), Up By 100.00% ($6.35) From $6.350 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/09/2019 09:22 PDT] CRMD Expected to Trade Up After Bullish Patterns Develop
• [05/13/2019 10:29 PDT] CorMedix, Inc. (NYSE:CRMD), Down By 100.00% ($7.98) From $7.980 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/01/2019 08:18 PDT] CRMD Expected to Trade Up After Bullish Patterns Develop
• [04/25/2019 07:57 PDT] CRMD Expected to Trade Down After Bearish Patterns Develop
• [04/18/2019 07:43 PDT] CRMD Expected to Trade Down Short Term